| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Deprescriptions | 9 | 2025 | 11 | 5.100 |
Why?
|
| Chronic Disease | 30 | 2024 | 398 | 5.060 |
Why?
|
| Dementia | 12 | 2025 | 136 | 3.280 |
Why?
|
| Primary Health Care | 20 | 2025 | 729 | 2.990 |
Why?
|
| Comorbidity | 23 | 2018 | 552 | 2.680 |
Why?
|
| Patient Care Team | 9 | 2019 | 107 | 2.330 |
Why?
|
| Cognitive Dysfunction | 6 | 2023 | 61 | 2.280 |
Why?
|
| Aged | 56 | 2025 | 6223 | 2.130 |
Why?
|
| Patient-Centered Care | 7 | 2020 | 190 | 2.080 |
Why?
|
| Humans | 100 | 2025 | 17622 | 2.070 |
Why?
|
| Multiple Chronic Conditions | 11 | 2024 | 22 | 2.040 |
Why?
|
| Male | 73 | 2025 | 10014 | 1.990 |
Why?
|
| Quality of Life | 14 | 2019 | 505 | 1.870 |
Why?
|
| Female | 73 | 2025 | 12715 | 1.810 |
Why?
|
| Delivery of Health Care | 9 | 2025 | 383 | 1.790 |
Why?
|
| Caregivers | 10 | 2025 | 136 | 1.690 |
Why?
|
| Health Status | 6 | 2017 | 291 | 1.520 |
Why?
|
| Aged, 80 and over | 27 | 2025 | 1976 | 1.510 |
Why?
|
| Patient Education as Topic | 3 | 2025 | 193 | 1.420 |
Why?
|
| Self Care | 7 | 2012 | 144 | 1.330 |
Why?
|
| Physicians, Primary Care | 6 | 2019 | 63 | 1.330 |
Why?
|
| Mental Disorders | 6 | 2020 | 276 | 1.260 |
Why?
|
| Depressive Disorder | 4 | 2012 | 186 | 1.190 |
Why?
|
| Attitude of Health Personnel | 5 | 2017 | 204 | 1.180 |
Why?
|
| Continuity of Patient Care | 4 | 2019 | 95 | 1.150 |
Why?
|
| Retrospective Studies | 26 | 2022 | 2502 | 1.120 |
Why?
|
| Outcome Assessment (Health Care) | 6 | 2017 | 213 | 1.060 |
Why?
|
| Communication | 5 | 2025 | 181 | 1.060 |
Why?
|
| Middle Aged | 38 | 2025 | 7954 | 1.030 |
Why?
|
| Qualitative Research | 10 | 2025 | 290 | 1.000 |
Why?
|
| Chronic Pain | 2 | 2022 | 133 | 0.990 |
Why?
|
| Colorado | 13 | 2025 | 170 | 0.970 |
Why?
|
| United States | 26 | 2023 | 3922 | 0.960 |
Why?
|
| Delivery of Health Care, Integrated | 5 | 2015 | 540 | 0.940 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2022 | 184 | 0.930 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2023 | 109 | 0.910 |
Why?
|
| Medication Adherence | 6 | 2022 | 232 | 0.850 |
Why?
|
| Cohort Studies | 18 | 2025 | 2502 | 0.820 |
Why?
|
| Health Services | 2 | 2017 | 110 | 0.810 |
Why?
|
| Self Efficacy | 3 | 2019 | 69 | 0.800 |
Why?
|
| Gastric Bypass | 2 | 2014 | 70 | 0.800 |
Why?
|
| Electronic Health Records | 4 | 2025 | 719 | 0.780 |
Why?
|
| Adult | 26 | 2024 | 7621 | 0.780 |
Why?
|
| Health Status Indicators | 2 | 2014 | 60 | 0.770 |
Why?
|
| Mental Health Services | 3 | 2019 | 155 | 0.750 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2017 | 308 | 0.740 |
Why?
|
| Hospitalization | 6 | 2023 | 831 | 0.720 |
Why?
|
| Health Plan Implementation | 2 | 2019 | 33 | 0.700 |
Why?
|
| Cholinergic Antagonists | 2 | 2019 | 7 | 0.700 |
Why?
|
| Food Supply | 1 | 2021 | 43 | 0.680 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2019 | 689 | 0.680 |
Why?
|
| Hypoglycemic Agents | 5 | 2019 | 259 | 0.680 |
Why?
|
| Health Services Needs and Demand | 4 | 2015 | 88 | 0.670 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2018 | 46 | 0.660 |
Why?
|
| Potentially Inappropriate Medication List | 1 | 2020 | 2 | 0.650 |
Why?
|
| Safety-net Providers | 2 | 2021 | 55 | 0.650 |
Why?
|
| Advance Directives | 1 | 2020 | 7 | 0.650 |
Why?
|
| Surveys and Questionnaires | 13 | 2022 | 1296 | 0.640 |
Why?
|
| Documentation | 1 | 2020 | 38 | 0.630 |
Why?
|
| Patient Portals | 1 | 2020 | 23 | 0.620 |
Why?
|
| Medicare Part D | 2 | 2010 | 15 | 0.600 |
Why?
|
| Cross-Sectional Studies | 14 | 2023 | 1295 | 0.600 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2021 | 380 | 0.590 |
Why?
|
| Diabetic Neuropathies | 2 | 2016 | 10 | 0.580 |
Why?
|
| Neoplasms | 3 | 2014 | 457 | 0.580 |
Why?
|
| Medicaid | 2 | 2022 | 188 | 0.580 |
Why?
|
| Health Promotion | 1 | 2021 | 293 | 0.570 |
Why?
|
| Diabetes Mellitus | 7 | 2017 | 452 | 0.570 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2021 | 368 | 0.560 |
Why?
|
| Specialization | 2 | 2017 | 21 | 0.560 |
Why?
|
| Hypolipidemic Agents | 3 | 2017 | 37 | 0.560 |
Why?
|
| Health Services Accessibility | 3 | 2017 | 269 | 0.560 |
Why?
|
| Telemedicine | 2 | 2024 | 196 | 0.560 |
Why?
|
| Hypertension | 7 | 2019 | 486 | 0.550 |
Why?
|
| Pain Management | 2 | 2015 | 58 | 0.540 |
Why?
|
| Obesity | 2 | 2014 | 821 | 0.530 |
Why?
|
| Laparoscopy | 2 | 2014 | 46 | 0.530 |
Why?
|
| Antihypertensive Agents | 5 | 2019 | 163 | 0.520 |
Why?
|
| Self Report | 5 | 2024 | 262 | 0.520 |
Why?
|
| Polypharmacy | 5 | 2025 | 15 | 0.520 |
Why?
|
| Severity of Illness Index | 3 | 2015 | 446 | 0.510 |
Why?
|
| Outcome and Process Assessment (Health Care) | 2 | 2017 | 96 | 0.510 |
Why?
|
| Medically Uninsured | 1 | 2017 | 41 | 0.500 |
Why?
|
| Quality Improvement | 5 | 2020 | 189 | 0.500 |
Why?
|
| Emergency Service, Hospital | 3 | 2015 | 402 | 0.490 |
Why?
|
| Bariatric Surgery | 2 | 2015 | 133 | 0.470 |
Why?
|
| Focus Groups | 5 | 2020 | 144 | 0.470 |
Why?
|
| Sleep Deprivation | 1 | 2015 | 3 | 0.460 |
Why?
|
| Neuralgia | 1 | 2015 | 2 | 0.460 |
Why?
|
| Patient Satisfaction | 3 | 2017 | 193 | 0.460 |
Why?
|
| Prostatic Neoplasms | 2 | 2014 | 262 | 0.460 |
Why?
|
| Referral and Consultation | 1 | 2017 | 161 | 0.460 |
Why?
|
| Preoperative Care | 1 | 2015 | 20 | 0.450 |
Why?
|
| Sickness Impact Profile | 2 | 2005 | 25 | 0.450 |
Why?
|
| Quality of Health Care | 2 | 2016 | 260 | 0.450 |
Why?
|
| Risk Assessment | 8 | 2024 | 1093 | 0.440 |
Why?
|
| Postoperative Care | 1 | 2015 | 16 | 0.440 |
Why?
|
| Gastroplasty | 1 | 2014 | 10 | 0.440 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 41 | 0.440 |
Why?
|
| Health Maintenance Organizations | 6 | 2012 | 403 | 0.440 |
Why?
|
| Osteoarthritis | 3 | 2008 | 15 | 0.420 |
Why?
|
| Drug Utilization | 2 | 2012 | 119 | 0.420 |
Why?
|
| Morbidity | 2 | 2012 | 59 | 0.420 |
Why?
|
| Interviews as Topic | 5 | 2025 | 324 | 0.410 |
Why?
|
| Colorectal Neoplasms | 3 | 2014 | 642 | 0.410 |
Why?
|
| Disease Progression | 2 | 2015 | 266 | 0.410 |
Why?
|
| Analgesics, Opioid | 2 | 2014 | 258 | 0.410 |
Why?
|
| Morphine | 1 | 2013 | 9 | 0.410 |
Why?
|
| Comparative Effectiveness Research | 1 | 2014 | 59 | 0.400 |
Why?
|
| Patient Compliance | 2 | 2008 | 269 | 0.390 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2013 | 168 | 0.390 |
Why?
|
| Cluster Analysis | 2 | 2020 | 90 | 0.380 |
Why?
|
| Models, Statistical | 1 | 2014 | 171 | 0.380 |
Why?
|
| Psychotherapy | 1 | 2012 | 56 | 0.360 |
Why?
|
| Research | 3 | 2018 | 60 | 0.360 |
Why?
|
| Perception | 3 | 2020 | 56 | 0.360 |
Why?
|
| Asthma | 2 | 2016 | 401 | 0.360 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2012 | 19 | 0.360 |
Why?
|
| International Classification of Diseases | 1 | 2012 | 85 | 0.350 |
Why?
|
| Patient Preference | 3 | 2022 | 49 | 0.350 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 142 | 0.340 |
Why?
|
| Patients | 1 | 2011 | 30 | 0.340 |
Why?
|
| Cardiovascular Diseases | 2 | 2014 | 545 | 0.330 |
Why?
|
| Depressive Disorder, Major | 1 | 2012 | 98 | 0.330 |
Why?
|
| Kidney Diseases | 1 | 2011 | 54 | 0.330 |
Why?
|
| Vaccination Refusal | 2 | 2021 | 10 | 0.320 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 158 | 0.320 |
Why?
|
| Pragmatic Clinical Trials as Topic | 2 | 2020 | 65 | 0.310 |
Why?
|
| Patient Participation | 4 | 2020 | 124 | 0.310 |
Why?
|
| Stakeholder Participation | 2 | 2020 | 21 | 0.310 |
Why?
|
| Psychometrics | 3 | 2018 | 119 | 0.310 |
Why?
|
| Medicare | 4 | 2022 | 197 | 0.310 |
Why?
|
| Socioeconomic Factors | 5 | 2020 | 603 | 0.300 |
Why?
|
| Delphi Technique | 4 | 2018 | 30 | 0.300 |
Why?
|
| Physicians | 2 | 2023 | 120 | 0.300 |
Why?
|
| Prognosis | 4 | 2014 | 609 | 0.300 |
Why?
|
| Cost of Illness | 2 | 2008 | 92 | 0.290 |
Why?
|
| Geriatrics | 1 | 2008 | 5 | 0.280 |
Why?
|
| Health Services for the Aged | 1 | 2008 | 14 | 0.280 |
Why?
|
| Parents | 2 | 2021 | 301 | 0.280 |
Why?
|
| Accidental Falls | 2 | 2019 | 50 | 0.280 |
Why?
|
| Disease Management | 4 | 2017 | 110 | 0.270 |
Why?
|
| Child, Preschool | 4 | 2021 | 1455 | 0.270 |
Why?
|
| Health Planning Guidelines | 1 | 2007 | 8 | 0.260 |
Why?
|
| Health Personnel | 2 | 2019 | 135 | 0.250 |
Why?
|
| Adolescent | 6 | 2015 | 3625 | 0.250 |
Why?
|
| Young Adult | 6 | 2016 | 2538 | 0.250 |
Why?
|
| Health Policy | 1 | 2007 | 106 | 0.240 |
Why?
|
| Infant | 3 | 2021 | 1228 | 0.240 |
Why?
|
| Multivariate Analysis | 5 | 2013 | 527 | 0.240 |
Why?
|
| Memantine | 1 | 2025 | 3 | 0.240 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2025 | 5 | 0.240 |
Why?
|
| Survival Rate | 3 | 2014 | 252 | 0.240 |
Why?
|
| Telephone | 2 | 2017 | 159 | 0.230 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 1157 | 0.230 |
Why?
|
| Age Factors | 6 | 2019 | 874 | 0.230 |
Why?
|
| Health Services Research | 3 | 2017 | 201 | 0.220 |
Why?
|
| Child | 4 | 2021 | 2485 | 0.220 |
Why?
|
| Dyslipidemias | 3 | 2019 | 54 | 0.220 |
Why?
|
| Alzheimer Disease | 1 | 2025 | 52 | 0.220 |
Why?
|
| Data Collection | 1 | 2005 | 234 | 0.220 |
Why?
|
| Nomograms | 2 | 2014 | 12 | 0.220 |
Why?
|
| Vaccination | 2 | 2021 | 726 | 0.220 |
Why?
|
| Maryland | 2 | 2024 | 17 | 0.220 |
Why?
|
| Treatment Outcome | 6 | 2025 | 1161 | 0.220 |
Why?
|
| Attitude | 2 | 2021 | 28 | 0.210 |
Why?
|
| Natural Language Processing | 1 | 2025 | 60 | 0.210 |
Why?
|
| Interdisciplinary Communication | 2 | 2014 | 18 | 0.210 |
Why?
|
| Physician-Patient Relations | 5 | 2016 | 168 | 0.210 |
Why?
|
| National Health Insurance, United States | 1 | 2003 | 1 | 0.210 |
Why?
|
| Single-Payer System | 1 | 2003 | 1 | 0.210 |
Why?
|
| Health Care Reform | 1 | 2003 | 20 | 0.200 |
Why?
|
| Longitudinal Studies | 3 | 2013 | 686 | 0.200 |
Why?
|
| Postoperative Complications | 2 | 2014 | 99 | 0.190 |
Why?
|
| Managed Care Programs | 2 | 2014 | 300 | 0.190 |
Why?
|
| Office Visits | 2 | 2017 | 75 | 0.190 |
Why?
|
| Interprofessional Relations | 2 | 2013 | 21 | 0.180 |
Why?
|
| Blood Pressure | 3 | 2019 | 288 | 0.180 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2022 | 73 | 0.170 |
Why?
|
| Attitude to Health | 2 | 2015 | 147 | 0.170 |
Why?
|
| Health Surveys | 3 | 2012 | 242 | 0.170 |
Why?
|
| Insulin | 2 | 2019 | 188 | 0.160 |
Why?
|
| Patient Care Management | 1 | 2020 | 24 | 0.160 |
Why?
|
| Fee-for-Service Plans | 2 | 2014 | 21 | 0.160 |
Why?
|
| Clergy | 1 | 2020 | 3 | 0.160 |
Why?
|
| Vaccines | 2 | 2020 | 225 | 0.160 |
Why?
|
| Anti-Vaccination Movement | 1 | 2019 | 1 | 0.160 |
Why?
|
| Residence Characteristics | 1 | 2022 | 256 | 0.160 |
Why?
|
| Southwestern United States | 1 | 2019 | 4 | 0.160 |
Why?
|
| Urban Health Services | 1 | 2019 | 11 | 0.150 |
Why?
|
| Religion | 1 | 2019 | 19 | 0.150 |
Why?
|
| Body Mass Index | 2 | 2014 | 959 | 0.150 |
Why?
|
| Databases, Factual | 3 | 2025 | 304 | 0.150 |
Why?
|
| Logistic Models | 5 | 2013 | 866 | 0.150 |
Why?
|
| Family | 1 | 2020 | 111 | 0.150 |
Why?
|
| Sulfonylurea Compounds | 1 | 2019 | 32 | 0.150 |
Why?
|
| Schools | 1 | 2019 | 91 | 0.150 |
Why?
|
| Metformin | 1 | 2019 | 52 | 0.140 |
Why?
|
| Comprehensive Health Care | 2 | 2017 | 8 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 208 | 0.140 |
Why?
|
| Research Design | 1 | 2020 | 337 | 0.140 |
Why?
|
| Contraindications, Drug | 1 | 2018 | 1 | 0.140 |
Why?
|
| Decision Making | 1 | 2019 | 177 | 0.140 |
Why?
|
| Multimorbidity | 1 | 2018 | 11 | 0.140 |
Why?
|
| Glycated Hemoglobin A | 3 | 2014 | 179 | 0.140 |
Why?
|
| Independent Living | 1 | 2018 | 24 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 33 | 0.140 |
Why?
|
| Prospective Studies | 2 | 2022 | 1251 | 0.130 |
Why?
|
| SEER Program | 2 | 2014 | 92 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2019 | 211 | 0.130 |
Why?
|
| Medication Therapy Management | 1 | 2017 | 5 | 0.130 |
Why?
|
| Electronics | 1 | 2017 | 3 | 0.130 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 27 | 0.130 |
Why?
|
| General Practice | 1 | 2016 | 6 | 0.130 |
Why?
|
| Case Management | 1 | 2017 | 29 | 0.130 |
Why?
|
| Depression | 3 | 2018 | 507 | 0.120 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2016 | 87 | 0.120 |
Why?
|
| Risk Factors | 5 | 2014 | 3291 | 0.120 |
Why?
|
| Health Education | 1 | 2016 | 82 | 0.120 |
Why?
|
| Activities of Daily Living | 2 | 2008 | 80 | 0.120 |
Why?
|
| Triazoles | 1 | 2016 | 2 | 0.120 |
Why?
|
| Nitriles | 1 | 2016 | 8 | 0.120 |
Why?
|
| Cooperative Behavior | 2 | 2014 | 87 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2017 | 214 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2017 | 155 | 0.120 |
Why?
|
| Validation Studies as Topic | 1 | 2015 | 11 | 0.120 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 702 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2016 | 65 | 0.110 |
Why?
|
| Hyperlipidemias | 2 | 2012 | 44 | 0.110 |
Why?
|
| Biliary Atresia | 1 | 1995 | 1 | 0.110 |
Why?
|
| Zinc | 1 | 1995 | 2 | 0.110 |
Why?
|
| Copper | 1 | 1995 | 4 | 0.110 |
Why?
|
| Manganese | 1 | 1995 | 3 | 0.110 |
Why?
|
| Liver | 1 | 1995 | 31 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 319 | 0.110 |
Why?
|
| Time Factors | 3 | 2012 | 1038 | 0.110 |
Why?
|
| Information Dissemination | 1 | 2014 | 50 | 0.110 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 2014 | 10 | 0.100 |
Why?
|
| Health Priorities | 1 | 2014 | 24 | 0.100 |
Why?
|
| Postoperative Period | 1 | 2013 | 14 | 0.100 |
Why?
|
| Pain | 1 | 2014 | 75 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 248 | 0.100 |
Why?
|
| Age Distribution | 1 | 2014 | 230 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2014 | 77 | 0.100 |
Why?
|
| Osteoarthritis, Knee | 1 | 2013 | 11 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 120 | 0.100 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2013 | 17 | 0.100 |
Why?
|
| Terminally Ill | 1 | 2013 | 9 | 0.100 |
Why?
|
| Obesity, Morbid | 1 | 2014 | 121 | 0.100 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2012 | 11 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2013 | 50 | 0.100 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 173 | 0.090 |
Why?
|
| Diabetes Complications | 1 | 2013 | 103 | 0.090 |
Why?
|
| Anticholesteremic Agents | 1 | 2012 | 13 | 0.090 |
Why?
|
| Primary Prevention | 1 | 2013 | 61 | 0.090 |
Why?
|
| Weight Loss | 1 | 2015 | 298 | 0.090 |
Why?
|
| Infection | 1 | 2012 | 17 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2012 | 35 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 2012 | 20 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 25 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 112 | 0.090 |
Why?
|
| Emigrants and Immigrants | 1 | 2012 | 27 | 0.090 |
Why?
|
| Data Mining | 1 | 2011 | 17 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 363 | 0.080 |
Why?
|
| Opioid-Related Disorders | 1 | 2014 | 185 | 0.080 |
Why?
|
| Incidence | 2 | 2014 | 1278 | 0.080 |
Why?
|
| Pandemics | 2 | 2024 | 295 | 0.080 |
Why?
|
| Algorithms | 1 | 2011 | 227 | 0.080 |
Why?
|
| Community Health Services | 1 | 2010 | 78 | 0.070 |
Why?
|
| Medical Records Systems, Computerized | 2 | 2007 | 67 | 0.070 |
Why?
|
| Prescription Fees | 1 | 2008 | 4 | 0.070 |
Why?
|
| California | 3 | 2024 | 2433 | 0.070 |
Why?
|
| Eligibility Determination | 1 | 2008 | 11 | 0.070 |
Why?
|
| Drug Utilization Review | 1 | 2008 | 22 | 0.070 |
Why?
|
| Self Disclosure | 1 | 2008 | 19 | 0.070 |
Why?
|
| Poisson Distribution | 1 | 2008 | 85 | 0.070 |
Why?
|
| Urban Population | 2 | 2012 | 111 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 1005 | 0.070 |
Why?
|
| Insurance Coverage | 1 | 2008 | 99 | 0.070 |
Why?
|
| Odds Ratio | 3 | 2014 | 631 | 0.070 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2007 | 23 | 0.070 |
Why?
|
| Treatment Refusal | 1 | 2007 | 30 | 0.070 |
Why?
|
| Reference Values | 2 | 2019 | 86 | 0.070 |
Why?
|
| Mass Screening | 1 | 2013 | 693 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2007 | 174 | 0.060 |
Why?
|
| Linear Models | 1 | 2007 | 204 | 0.060 |
Why?
|
| Heart Failure | 1 | 2012 | 414 | 0.060 |
Why?
|
| Social Support | 1 | 2007 | 215 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 2007 | 141 | 0.060 |
Why?
|
| Self Concept | 1 | 2005 | 39 | 0.060 |
Why?
|
| Choice Behavior | 1 | 2005 | 45 | 0.060 |
Why?
|
| Goals | 1 | 2005 | 28 | 0.060 |
Why?
|
| Chicago | 1 | 2004 | 25 | 0.050 |
Why?
|
| Boston | 1 | 2004 | 31 | 0.050 |
Why?
|
| Medicine | 1 | 2004 | 17 | 0.050 |
Why?
|
| Los Angeles | 1 | 2004 | 150 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2004 | 268 | 0.050 |
Why?
|
| Self-Management | 1 | 2024 | 27 | 0.050 |
Why?
|
| Health Behavior | 1 | 2005 | 348 | 0.050 |
Why?
|
| Cholesterol, LDL | 2 | 2014 | 117 | 0.050 |
Why?
|
| Housing | 1 | 2022 | 37 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 144 | 0.040 |
Why?
|
| Biomarkers | 2 | 2013 | 302 | 0.040 |
Why?
|
| Health Expenditures | 1 | 2022 | 72 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2001 | 16 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2020 | 4 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 2020 | 11 | 0.040 |
Why?
|
| Assisted Living Facilities | 1 | 2020 | 1 | 0.040 |
Why?
|
| Nursing Homes | 1 | 2020 | 11 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 26 | 0.040 |
Why?
|
| Mortality | 1 | 2020 | 116 | 0.040 |
Why?
|
| Hospitals | 1 | 2020 | 71 | 0.040 |
Why?
|
| Prevalence | 1 | 2022 | 830 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 104 | 0.040 |
Why?
|
| Hispanic Americans | 1 | 2021 | 370 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2018 | 35 | 0.040 |
Why?
|
| Fatigue | 1 | 2018 | 30 | 0.040 |
Why?
|
| Sleep Wake Disorders | 1 | 2018 | 33 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 41 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 43 | 0.030 |
Why?
|
| Ethnic Groups | 1 | 2020 | 443 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2017 | 16 | 0.030 |
Why?
|
| Aging | 1 | 2018 | 159 | 0.030 |
Why?
|
| Anxiety | 1 | 2018 | 162 | 0.030 |
Why?
|
| Mental Health | 1 | 2018 | 163 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2007 | 137 | 0.030 |
Why?
|
| Automation | 1 | 2016 | 24 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 237 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 26 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 55 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2016 | 50 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 53 | 0.030 |
Why?
|
| Aromatase Inhibitors | 1 | 2016 | 33 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 114 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2016 | 55 | 0.030 |
Why?
|
| Veterans | 1 | 2017 | 149 | 0.030 |
Why?
|
| Postmenopause | 1 | 2016 | 251 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 73 | 0.030 |
Why?
|
| Forecasting | 1 | 2014 | 68 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2014 | 66 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2014 | 66 | 0.030 |
Why?
|
| Reoperation | 1 | 2013 | 24 | 0.020 |
Why?
|
| Remote Consultation | 1 | 2013 | 9 | 0.020 |
Why?
|
| Patient Access to Records | 1 | 2013 | 12 | 0.020 |
Why?
|
| Electronic Mail | 1 | 2013 | 51 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 4 | 0.020 |
Why?
|
| Etanercept | 1 | 2012 | 4 | 0.020 |
Why?
|
| Infliximab | 1 | 2012 | 6 | 0.020 |
Why?
|
| Antirheumatic Agents | 1 | 2012 | 12 | 0.020 |
Why?
|
| Turkey | 1 | 2012 | 1 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 27 | 0.020 |
Why?
|
| London | 1 | 2012 | 6 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2012 | 11 | 0.020 |
Why?
|
| United Kingdom | 1 | 2012 | 25 | 0.020 |
Why?
|
| Internet | 1 | 2013 | 207 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2012 | 35 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2013 | 163 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 492 | 0.020 |
Why?
|
| Empathy | 1 | 2010 | 8 | 0.020 |
Why?
|
| Registries | 1 | 2012 | 475 | 0.020 |
Why?
|
| Learning | 1 | 2010 | 18 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 599 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2010 | 54 | 0.020 |
Why?
|
| Holistic Health | 1 | 2007 | 2 | 0.020 |
Why?
|
| CD-ROM | 1 | 2005 | 3 | 0.010 |
Why?
|
| Nonlinear Dynamics | 1 | 2005 | 7 | 0.010 |
Why?
|
| Computer-Assisted Instruction | 1 | 2005 | 10 | 0.010 |
Why?
|
| Diet, Fat-Restricted | 1 | 2005 | 36 | 0.010 |
Why?
|
| Fruit | 1 | 2005 | 79 | 0.010 |
Why?
|
| Vegetables | 1 | 2005 | 88 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2005 | 45 | 0.010 |
Why?
|
| Exercise | 1 | 2005 | 538 | 0.010 |
Why?
|